BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 31771790)

  • 1. NSCLC patient "migration" for treatment: A retrospective analysis of patient characteristics, travel patterns, and survival differences.
    Pham D; Bhandari S; Pinkston C; Oechsli M; Kloecker G
    Curr Probl Cancer; 2020 Aug; 44(4):100528. PubMed ID: 31771790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distance from accessible specialist care and other determinants of advanced or unknown stage at diagnosis of people with non-small cell lung cancer: A data linkage study.
    Tracey E; McCaughan B; Badgery-Parker T; Young J; Armstrong B
    Lung Cancer; 2015 Oct; 90(1):15-21. PubMed ID: 26275475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival of Australian lung cancer patients and the impact of distance from and attendance at a thoracic specialist centre: a data linkage study.
    Tracey E; McCaughan B; Badgery-Parker T; Young J; Armstrong B
    Thorax; 2015 Feb; 70(2):152-60. PubMed ID: 25074705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insurance Status is an Independent Predictor of Overall Survival in Patients With Stage III Non-small-cell Lung Cancer Treated With Curative Intent.
    Rice SR; Vyfhuis MAL; Scilla KA; Burrows WM; Bhooshan N; Suntharalingam M; Edelman MJ; Feliciano J; Badiyan SN; Simone CB; Bentzen SM; Feigenberg SJ; Mohindra P
    Clin Lung Cancer; 2020 May; 21(3):e130-e141. PubMed ID: 31708388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Care and Outcomes of Older Persons with Lung Cancer in England and the United States, 2008-2012.
    Andreano A; Peake MD; Janes SM; Valsecchi MG; Pritchard-Jones K; Hoag JR; Gross CP
    J Thorac Oncol; 2018 Jul; 13(7):904-914. PubMed ID: 29727739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Japanese lung cancer registry study on demographics and treatment modalities in medically treated patients.
    Sekine I; Shintani Y; Shukuya T; Takayama K; Inoue A; Okamoto I; Kiura K; Takahashi K; Dosaka-Akita H; Takiguchi Y; Miyaoka E; Okumura M; Yoshino I
    Cancer Sci; 2020 May; 111(5):1685-1691. PubMed ID: 32103551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors in stage III non-small-cell lung cancer.
    Ademuyiwa FO; Johnson CS; White AS; Breen TE; Harvey J; Neubauer M; Hanna NH
    Clin Lung Cancer; 2007 Sep; 8(8):478-82. PubMed ID: 17922971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.
    Yao ZH; Liao WY; Ho CC; Chen KY; Shih JY; Chen JS; Lin ZZ; Lin CC; Chih-Hsin Yang J; Yu CJ
    Oncologist; 2017 Sep; 22(9):1075-1083. PubMed ID: 28507206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second malignancy in non-small cell lung cancer (NSCLC): prevalence and overall survival (OS) in routine clinical practice.
    Faehling M; Schwenk B; Kramberg S; Fallscheer S; Leschke M; Sträter J; Eckert R
    J Cancer Res Clin Oncol; 2018 Oct; 144(10):2059-2066. PubMed ID: 30062488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of survival for younger patients less than 50 years of age with non-small cell lung cancer (NSCLC): a California Cancer Registry analysis.
    Lara MS; Brunson A; Wun T; Tomlinson B; Qi L; Cress R; Gandara DR; Kelly K
    Lung Cancer; 2014 Aug; 85(2):264-9. PubMed ID: 24878033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real world utilization of EGFR TKIs and prognostic factors for survival in NSCLC during 2010-2016 in Sweden: A nationwide observational study.
    Bergqvist M; Christensen HN; Wiklund F; Bergström S
    Int J Cancer; 2020 May; 146(9):2510-2517. PubMed ID: 31350754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-small Cell Lung Cancer as a Chronic Disease - A Prospective Study from the Czech TULUNG Registry.
    Bratova M; Karlinova B; Skrickova J; Pesek M; Kolek V; Koubkova L; Hrnciarik M; Krejci J; Barinova M; Havel L; Grygarkova I; Brat K
    In Vivo; 2020; 34(1):369-379. PubMed ID: 31882501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis.
    Kuiper JL; Hendriks LE; van der Wekken AJ; de Langen AJ; Bahce I; Thunnissen E; Heideman DA; Berk Y; Buijs EJ; Speel EJ; Krouwels FH; Smit HJ; Groen HJ; Dingemans AM; Smit EF
    Lung Cancer; 2015 Sep; 89(3):255-61. PubMed ID: 26117231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival results and prognostic factors in T4 N0-3 non-small cell lung cancer patients according to the AJCC 7th edition staging system.
    Arslan D; Bozcuk H; Gunduz S; Tural D; Tattli AM; Uysal M; Goksu SS; Bassorgun Cİ; Koral L; Coskun HS; Ozdogan M; Savas B
    Asian Pac J Cancer Prev; 2014; 15(6):2465-72. PubMed ID: 24761848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Survival Rates After a Combination of Local Treatment and Systemic Therapy vs Systemic Therapy Alone for Treatment of Stage IV Non-Small Cell Lung Cancer.
    Uhlig J; Case MD; Blasberg JD; Boffa DJ; Chiang A; Gettinger SN; Kim HS
    JAMA Netw Open; 2019 Aug; 2(8):e199702. PubMed ID: 31433481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment Patterns and Differences in Survival of Non-Small Cell Lung Cancer Patients Between Academic and Non-Academic Hospitals in the Netherlands.
    van der Linden N; Bongers ML; Coupé VMH; Smit EF; Groen HJM; Welling A; Schramel FMNH; Uyl-de Groot CA
    Clin Lung Cancer; 2017 Sep; 18(5):e341-e347. PubMed ID: 28347579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population-based patterns of treatment and survival for patients with stage I and II non-small cell lung cancer aged 65-74 years and 75 years or older.
    Driessen E; Detillon D; Bootsma G; De Ruysscher D; Veen E; Aarts M; Janssen-Heijnen M
    J Geriatr Oncol; 2019 Jul; 10(4):547-554. PubMed ID: 30876833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative.
    Soares M; Antunes L; Redondo P; Borges M; Hermans R; Patel D; Grimson F; Munro R; Chaib C; Lacoin L; Daumont M; Penrod JR; O'Donnell JC; Bento MJ; Rocha Gonçalves F
    BMC Pulm Med; 2020 Sep; 20(1):240. PubMed ID: 32912174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990.
    Wakelee HA; Bernardo P; Johnson DH; Schiller JH
    Cancer; 2006 May; 106(10):2208-17. PubMed ID: 16604529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inpatients versus outpatients with advanced non-small cell lung cancer: Characteristics and outcomes.
    Gotfrit J; Jonker C; Zhang T; Goss G; Nicholas G; Laurie S; Wheatley-Price P
    Cancer Treat Res Commun; 2019; 19():100130. PubMed ID: 30927666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.